# EDGAR Filing Document

**Accession Number:** 0001832285
**File Stem:** 0001062993-25-011543
**Filing Date:** 2025-6
**Character Count:** 9478
**Document Hash:** 44276056e813c82f8765a17014108f2b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-011543.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001062993-25-011543

**CONFORMED SUBMISSION TYPE**: 3/A

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250605

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Chandrasekhar Satishchandran
- **CENTRAL INDEX KEY:** 0001832285

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36751
- **FILM NUMBER:** 251043178

**MAIL ADDRESS:**
- **STREET 1:** 167 CARMELA COURT
- **CITY:** JUPITER
- **STATE:** FL
- **ZIP:** 33478
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ocugen, Inc.
- **CENTRAL INDEX KEY:** 0001372299
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 11 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 484-328-4701

**MAIL ADDRESS:**
- **STREET 1:** 11 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HISTOGENICS CORP
- **DATE OF NAME CHANGE:** 20060810

## Exhibit 24.1

```

			POWER OF ATTORNEY

       Know all by these present, that I, the undersigned director
and/or officer of Ocugen, Inc., a Delaware corporation (the "Company"),
hereby constitute and appoint Shankar Musunuri and Ramesh Ramachandran as
my true and lawful attorneys-in-fact and agents, with full power to act,
together or each without the other, with full power of substitution and
resubstitution, for me and in my name, place and stead, in any and all
capacities:

       (i)	to execute and file for and on behalf of the undersigned
any reports on Forms 3, 4 and 5 (including any amendments thereto and any
successors to such Forms) with respect to ownership acquisition or
disposition of securities of the Company that the undersigned may be
required to file with the U.S. Securities and Exchange Commission (the "SEC")
in accordance with Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), and the rules promulgated thereunder;

	(ii)	to execute and file for and on behalf of the undersigned any
voluntary filings under Section 16(a) of the Exchange Act;

	(iii)	to request electronic filing codes from the SEC by filing the
Form ID (including amendments thereto) and any other documents necessary or
appropriate to obtain codes and passwords enabling the undersigned to file
such reports electronically;

       (iv)	to prepare, file, and submit any documents or reports that
may be required under SEC Rule 144 to permit the undersigned to sell Company
common stock without registration under the Securities Act of 1933, as amended
(the "Securities Act") in reliance on Rule 144 as amended from time to time; or

       (v)	take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorneys-in-fact, may be of
benefit to, in the best interest of, or legally required by, the undersigned,
it being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such attorneys-in-fact may
approve in such attorneys-in-fact's discretion.

       The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to
comply with Section 16(a) of the Exchange Act or the Securities Act. The
Company will use all reasonable efforts to apprise the undersigned of
applicable filing requirements for purposes of Section 16(a) of the Exchange
Act or the Securities Act.

       This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4 and 5 with respect
to the undersigned's holdings and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact. This Power of Attorney
revokes and replaces any prior Power of Attorney executed by the
undersigned with respect to the ownership, acquisition or disposition of
securities of the Company.

       IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this May 1, 2025.

/s/ Satishchandran Chandrasekhar
Signature

Satishchandran Chandrasekhar
Print Name

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Chandrasekhar Satishchandran<br><sub>(Last) (First) (Middle)</sub><br>C/O OCUGEN, INC.<br>11 GREAT VALLEY PARKWAY<br><sub>(Street)</sub><br>MALVERN, PA 19355<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-05 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Ocugen, Inc. [ OCGN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $2.22 |  |  |  |  |  |  | <sup>(1)</sup> | 2031-01-15 | Common Stock | 25000 |  |  | D |  |
| Stock Option (right to buy) | $4.25 |  |  |  |  |  |  | <sup>(1)</sup> | 2032-01-15 | Common Stock | 10000 |  |  | D |  |

---

### Footnotes:

(1) This option is fully vested and exercisable.

**Remarks:**
This amendment to the Form 3 originally filed on June 9, 2025, is being filed solely to include two grants of employee stock options that were inadvertently omitted from the original filing due to an administrative error.

**Signature:** /s/ Satish Chandran by Shankar Musunuri, his attorney-in-fact  
**Date:** 2025-06-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**